ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025
Assessment of toxicity in patients with ultra-central thoracic tumours treated with stereotactic body radiotherapy with a dose of 50 Gy in 5 fractions.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Superior vena cava syndrome in non-lung primary tumours treated with palliative intent.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stereotactic body radiotherapy (SBRT) is a well-accepted treatment for metastatic and primary lung cancer; however, an optimal regimen is still unclear for ultra central thoracic lesions. The objective of this manuscript is to report the toxicity of SBRT in patients with ultra-central tumors treated with 50 Gy in 5 fractions. Materials and methods: We performed a retrospective review of patients with ultra-central lung lesions treated with SBRT in our institution at the dose of 50 Gy in 5 fractions, delivered every other day. Lesions were defined as ultra-central when the planning target volume (PTV) overlapped the trachea, proximal bronchial tree, great vessels, heart and esophagus. Constraints for organ at risk (OAR) were the ones used in the RTOG-0813 trial. Results: 86 patients were included in this review. The median age was 74 years. The overlapping OAR were: the great vessels in 46 patients (53.4%), heart in 20 (23.2%), tracheobronchial tree in 18 (20.9%) and esophagus in 2 (2.3%). Median follow up was 17 months. The median overall survival was 39 months. There was no SBRT related grade 3 or greater acute or late toxicity. Conclusion: In this cohort of patients with ultra-central thoracic lesions treated with 50 Gy in 5 fraction SBRT, no grade 3-5 acute or late toxicity was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.